ABC | Volume 113, Nº4, Outubro 2019

Atualização Atualização da Diretriz de Prevenção Cardiovascular da Sociedade Brasileira de Cardiologia – 2019 Arq Bras Cardiol. 2019; 113(4):787-891 67. Haas SJ, Vos T, Gilbert RE, Krum H. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? Ameta-analysis of large-scale clinical trials. Am Heart J. 2003;146(5):848-53. 68. Taylor AL, Ziesche S, Yancy CW, Carson P, Ferdinand K, Taylor M, et al. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/ hydralazine: consistency across subgroups in the African-AmericanHeart Failure Trial. Circulation. 2007;115(13):1747-53. 69. Komajda M, Tavazzi L, Francq BG, Böhm M, Borer JS, Ford I, et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. Eur J Heart Fail. 2015;17(12):1294-301. 70. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25(7):1129-34. 71. Ning F, Tuomilehto J, Pyörälä K, Onat A, Söderberg S, Qiao Q, et al. Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range. Diabetes Care. 2010;33(10):2211-6. 72. Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379(9833):2279-90. 73. Hollingsworth KG, Al-Mrabeh A, Steven S, Taylor R. Pancreatic triacylglycerol distribution in type 2 diabetes. Diabetologia. 2015;58(11):2676-8. 74. Task Force Members, Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34(39):3035-87. 75. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the FinnishDiabetes Prevention Study. Lancet. 2006;368(9548):1673-9. 76. Li G, Zhang P, Wang J, An Y, Gong Q, Gregg EW, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2014;2(6):474-80. 77. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580-91. 78. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation. 2013;127(1):143-52. 79. Malta DC, Felisbino-Mendes MS, Machado IE, Passos VMA, Abreu DMX, Ishitani LH, et al. Risk factors related to the global burden of disease in Brazil and its FederatedUnits, 2015. Rev Bras Epidemiol. 2017;20 (Suppl 01):217-32. 80. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113-32. 81. Muhlestein JB, LappeDL, Lima JA, Rosen BD,MayHT, Knight S, et al. Effect of screening for coronary artery disease using CT angiography onmortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. JAMA. 2014;312(21):2234-43. 82. Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA. 2009;301(15):1547-55. 83. Lievre MM, Moulin P, Thivolet C, Rodier M, Rigalleau V, Penfornis A, et al. Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening. Trials. 2011 Jan 26;12:23. 84. Cox AJ, Hsu FC, Freedman BI, Herrington DM, Criqui MH, Carr JJ, et al. Contributors to mortality in high-risk diabetic patients in the Diabetes Heart Study. Diabetes Care. 2014;37(10):2798-803. 85. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-39. 86. King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999;48(5):643-8. 87. van der Leeuw J, vanDieren S, Beulens JW, BoeingH, Spijkerman AM, van der Graaf Y, et al. The validation of cardiovascular risk scores for patients with type 2 diabetes mellitus. Heart. 2015;101(3):222-9. 88. AhnHR, ShinMH, YunWJ, KimHY, Lee YH, Kweon SS, et al. Comparison of the Framingham Risk Score, UKPDS Risk Engine, and SCORE for Predicting Carotid Atherosclerosis and Peripheral Arterial Disease in Korean Type 2Diabetic Patients. Korean J FamMed. 2011;32(3):189-96. 89. Song SH, Brown PM. Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabet Med. 2004;21(3):238-45. 90. Pletcher MJ, Pignone M, Earnshaw S, McDade C, Phillips KA, Auer R, et al. Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes. 2014;7(2):276-84. 91. Gupta A, Lau E, Varshney R, Hulten EA, Cheezum M, Bittencourt MS, et al. The Identification of calcified coronary plaque is associated with initiation and continuation of pharmacological and lifestyle preventive therapies: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 2017;10(8):833-42. 92. McClelland RL, Jorgensen NW, Budoff M, Blaha MJ, Post WS, Kronmal RA, et al. 10-Year Coronary Heart Disease Risk PredictionUsing Coronary Artery Calcium and Traditional Risk Factors: Derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) With Validation in theHNR (Heinz Nixdorf Recall) Study and theDHS (Dallas Heart Study). J AmColl Cardiol. 2015;66(15):1643-53. 93. Blaha MJ, Budoff MJ, DeFilippis AP, Blankstein R, Rivera JJ, Agatston A, et al. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA,apopulation-basedcohortstudy.Lancet.2011;378(9792):684-92. 94. Nasir K, Bittencourt MS, BlahaMJ, Blankstein R, Agatson AS, Rivera JJ, et al. Implications of Coronary Artery CalciumTesting Among Statin Candidates According to AmericanCollege of Cardiology/AmericanHeart Association Cholesterol Management Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2015;66(15):1657-68. 95. Nicholls SJ, BallantyneCM, Barter PJ, ChapmanMJ, Erbel RM, Libby P, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078-87. 96. Ford I, MurrayH, PackardCJ, Shepherd J, Macfarlane PW, Cobbe SM, et al. Long-term follow-up of theWest of Scotland Coronary Prevention Study. N Engl J Med. 2007;357(15):1477-86. 97. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387-97. 98. SabatineMS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA,etal.Evolocumabandclinicaloutcomes inpatientswithcardiovascular disease. N Engl J Med. 2017;376(18):1713-22. 875